Evaluating blood markers for diagnosing a serious clotting condition
The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation
Qilu Hospital of Shandong University · NCT05995093
This study is testing if certain blood markers can help doctors quickly diagnose a serious clotting condition called DIC to improve treatment and save lives.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 462 (estimated) |
| Ages | 18 Years to 94 Years |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ji'nan, Shandong) |
| Trial ID | NCT05995093 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on disseminated intravascular coagulation (DIC), a critical condition that requires prompt diagnosis for effective treatment. The research, conducted by Qilu Hospital of Shandong University, aims to assess the diagnostic performance of various hemostatic biomarkers, such as thrombin-antithrombin complex and soluble thrombomodulin, to identify DIC in its reversible phase. By improving early detection, the study seeks to enhance treatment outcomes and reduce mortality associated with DIC.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized adults aged 18 and older who have been admitted for at least three days.
Not a fit: Patients with primary hematologic diseases, decompensated liver cirrhosis, or a history of chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of DIC, improving patient management and outcomes.
How similar studies have performed: While the approach of using hemostatic biomarkers for DIC diagnosis is promising, it is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old, non-perinatal period, a hospitalization length of≥3 days. Exclusion Criteria: * primary hematologic diseases, decompensated liver cirrhosis, chemotherapy history.
Where this trial is running
Ji'nan, Shandong
- Miao Xu — Ji'nan, Shandong, China (RECRUITING)
Study contacts
- Principal investigator: Miao Xu — Qilu Hospital of Shandong University
- Study coordinator: Miao Xu
- Email: miao.xu@sdu.edu.cn
- Phone: 0531-82169885
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Disseminated Intravascular Coagulation, Thrombosis, Coagulation, Hemostatic Biomarkers, DIC